These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21208484)

  • 1. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients.
    Silver H; Mandiuk N; Einoch R; Susser E; Danovich L; Bilker W; Youdim M; Weinreb O
    Int Clin Psychopharmacol; 2015 May; 30(3):158-66. PubMed ID: 25756551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
    Einoch R; Weinreb O; Mandiuk N; Youdim MBH; Bilker W; Silver H
    Eur Neuropsychopharmacol; 2017 May; 27(5):470-483. PubMed ID: 28410959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine.
    Chertkow Y; Weinreb O; Youdim MB; Silver H
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1356-62. PubMed ID: 17662512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.
    Danovich L; Weinreb O; Youdim MB; Silver H
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):143-55. PubMed ID: 20181299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
    Silver H; Chertkow Y; Weinreb O; Danovich L; Youdim M
    Neurotherapeutics; 2009 Jan; 6(1):86-93. PubMed ID: 19110201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Expert Opin Pharmacother; 2004 Oct; 5(10):2053-8. PubMed ID: 15461540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex.
    Danovich L; Weinreb O; Youdim MB; Silver H
    Psychopharmacology (Berl); 2012 Apr; 220(4):763-70. PubMed ID: 21989809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions.
    Silver H; Einoch R; Youdim M; Weinreb O
    Curr Med Chem; 2013; 20(3):363-70. PubMed ID: 23157628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
    Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):305-13. PubMed ID: 14571150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
    Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
    Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.